Comparison · NCT00791648-sae
Statin vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Statin vs Placebo: serious adverse events. Trial comparisons, record NCT00791648-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00791648-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0455 | 0.0273 | 0.0748 | wilson | |
| Risk in group 2 | 0.0619 | 0.04 | 0.0946 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0164 | -0.0539 | 0.0202 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.734 | 0.375 | 1.44 | log | |
| Odds ratio, group 1 over group 2 | 0.722 | 0.355 | 1.47 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Statin than on Placebo | 60.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Statin | atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1. | 14 | 308 | EG000 |
| Group 2 | Placebo | placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1. | 19 | 307 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- First 10 post-op days
Source ClinicalTrials.gov
Trial
- Title
- Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery
- NCT number
- NCT00791648
- Phases
- NA
- Conditions
- Acute Kidney Injury, Post-Operative Delirium, Icu Delirium, Acute Renal Failure, Delirium
- Interventions
- atorvastatin, placebo
- Lead sponsor
- Vanderbilt University Medical Center
- Results first posted
- 2017-03-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00791648?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00791648-sae